Summit Therapeutics/$SMMT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Summit Therapeutics
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.
Ticker
$SMMT
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
159
ISIN
US86627T1088
Website
SMMT Metrics
BasicAdvanced
$15B
-
-$0.34
-0.46
-
Price and volume
Market cap
$15B
Beta
-0.46
52-week high
$36.91
52-week low
$6.78
Average daily volume
4.3M
Financial strength
Current ratio
10.63
Quick ratio
10.36
Long term debt to equity
0.844
Total debt to equity
1.873
Interest coverage (TTM)
-42.31%
Profitability
EBITDA (TTM)
-235.366
Management effectiveness
Return on assets (TTM)
-52.50%
Return on equity (TTM)
-123.93%
Valuation
Price to book
42.75
Price to tangible book (TTM)
42.99
Price to free cash flow (TTM)
-76.539
Free cash flow yield (TTM)
-1.31%
Free cash flow per share (TTM)
-25.93%
Growth
Earnings per share change (TTM)
105.02%
3-year earnings per share growth (CAGR)
-29.38%
What the Analysts think about SMMT
Analyst ratings (Buy, Hold, Sell) for Summit Therapeutics stock.
Bulls say / Bears say
Summit Therapeutics' experimental lung cancer drug demonstrated a median progression-free survival of over 11 months, significantly outperforming Merck's Keytruda in a head-to-head study, leading to a 37% surge in Summit's shares. (reuters.com)
The company secured a $235 million private financing in September 2024, bolstering its cash reserves to approximately $487 million, providing substantial resources for ongoing and future clinical trials. (biospace.com)
Summit Therapeutics has expanded its collaboration with Pfizer to accelerate the development of new cancer therapies, with clinical trials expected to commence by mid-2025, potentially enhancing its pipeline and market position. (tipranks.com)
Despite promising clinical results, Summit's experimental drug remains years away from market approval, with global late-stage trials only set to begin in 2025, delaying potential revenue streams. (reuters.com)
The company reported a net loss of $62.9 million for Q1 2025, an increase from the previous year's loss of $43.5 million, indicating ongoing financial challenges. (biospace.com)
Summit's research and development expenses have significantly increased, rising to $51.2 million in Q1 2025 from $30.9 million in Q1 2024, which may strain financial resources if not offset by future revenues. (biospace.com)
Data summarised monthly by Lightyear AI. Last updated on 9 Jun 2025.
SMMT Financial Performance
Revenues and expenses
SMMT Earnings Performance
Company profitability
SMMT News
AllArticlesVideos
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
GlobeNewsWire·1 hour ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
Accesswire·2 days ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
GlobeNewsWire·3 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Summit Therapeutics stock?
Summit Therapeutics (SMMT) has a market cap of $15B as of June 18, 2025.
What is the P/E ratio for Summit Therapeutics stock?
The price to earnings (P/E) ratio for Summit Therapeutics (SMMT) stock is 0 as of June 18, 2025.
Does Summit Therapeutics stock pay dividends?
No, Summit Therapeutics (SMMT) stock does not pay dividends to its shareholders as of June 18, 2025.
When is the next Summit Therapeutics dividend payment date?
Summit Therapeutics (SMMT) stock does not pay dividends to its shareholders.
What is the beta indicator for Summit Therapeutics?
Summit Therapeutics (SMMT) has a beta rating of -0.46. This means that it has an inverse relation to market volatility.